¼¼°èÀÇ ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü(BTC) ½ÃÀå - ÀÓ»ó½ÃÇè, µ¶ÀÚÀûÀÎ Ç÷§Æû, ½ÃÀå ±âȸ(2025³â)
Global Bicycle Toxin Conjugates Clinical Trials, Proprietary Platforms & Market Opportunity Insight 2025
»óǰÄÚµå : 1799230
¸®¼­Ä¡»ç : KuicK Research
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 55 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,000 £Ü 4,228,000
PDF (Single User License) help
º¸°í¼­ PDF¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ¸¸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,000 £Ü 7,047,000
PDF (Multi-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü ½ÃÀå - ÀÓ»ó½ÃÇè, µ¶ÀÚÀûÀÎ Ç÷§Æû, ½ÃÀå ±âȸ(2025) º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕüÀÇ Çʿ伺 ¹× º» º¸°í¼­ÀÇ ÀǹÌ

º¸´Ù ¾ÈÀüÇϰí, º¸´Ù È¿°úÀûÀ̰í, Ç¥Àû¼ºÀÌ ³ôÀº Ç×¾ÏÁ¦ Ä¡·á¿¡ ´ëÇÑ ¿ä±¸ÀÇ °íÁ¶°¡ »õ·Î¿î Ä¡·á¹ýÀ» ÇâÇÑ Ã¢¾àÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü(BTC)´Â ½Å¼¼´ëÀÇ Ç¥Àû Ä¡·áÁ¦·Î, Á¤¹Ðµµ°¡ ³ô°í, ¾çÈ£ÇÑ ¾àµ¿ÇÐ, Á¾¾ç¿¡ ´ëÇÑ Ä§Åõ¼º µîÀ» Ư¡À¸·Î ÇÕ´Ï´Ù. ¹ÙÀÌ»çÀÌŬ¸¯ ÆéƼµåÀÇ °áÇÕ Ä£È­¼º ¹× È­Çпä¹ýÁ¦ÀÇ ¼¼Æ÷ µ¶¼º ÆäÀ̷ε带 Á¶ÇÕÇÔÀ¸·Î½á BTC´Â Àü½Åµ¶¼ºÀ» ¾ïÁ¦Çϸ鼭 ¸Å¿ì È¿°úÀûÀÎ Ç×¾ÏȰ¼ºÀ» ¹ßÈÖÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕüÀÇ ¿µ¿ªÀÌ Ãʱâ ÀÓ»óÀû À¯¸Á¼º¿¡¼­ È®½ÇÇÑ ¼º°ú·Î ÀÌÇàÇÏ´Â µ¿¾È ½Ã±âÀûÀýÇϰí Áß¿äÇÕ´Ï´Ù. ÀÌ ¿µ¿ªÀº ¾ÆÁ÷ ¿©¸í±âÀÌÁö¸¸ ÀÓ»ó ÁøÀü, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ¿¬±¸ ÅõÀÚÀÇ ¼Óµµ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. º» ºÐ¼®Àº ¹ÙÀ̽ÃŬ·çÅå½Å Á¢ÇÕü°¡ °úÇÐÀû, ÀÓ»óÀû, »ó¾÷ÀûÀ¸·Î ÇöÀç ¾î´À ´Ü°è¿¡ ÀÖ´ÂÁö¸¦ Á¾ÇÕÀûÀ¸·Î Àü¸ÁÇϰí, ÀÌÇØ°ü°èÀÚ¿¡°Ô Á¾¾çÇÐ ¹× ±× ÀÌÈÄÀÇ ¹Ì·¡ º¥Ä¡¸¶Å©¸¦ À籸¼ºÇÒ ¼ö ÀÖ´Â ±Þ¼ÓÇÏ°Ô ¹ßÀüÇϰí ÀÖ´Â ¿µ¿ª¿¡ ´ëÇÑ Áß¿äÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.

º¸°í¼­¿¡ Æ÷ÇÔµÈ ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ÀλçÀÌÆ®

ÀÌ º¸°í¼­´Â ÇöÀç ÁøÇàÁßÀÎ ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü ÀÓ»ó½ÃÇèÀÇ »óȲÀ» »ó¼¼ÇÏ°Ô ¿ä¾àÇϰí ÃÊ±â ¹× Á߱⠴ܰ迡¼­ ÁÖ¿ä Ä¡·áÁ¦ Èĺ¸ÀÇ °³¹ßÀ» ¿ä¾àÇÕ´Ï´Ù. Bicycle Therapeutics°¡ ¸¸µç ¼¼ °¡Áö ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü, Áï BT1718, BT5528, zelenectide pevedotin(Zele, BT8009)Àº ÃÊ±â ¹× Èıâ ÀÓ»ó½ÃÇè¿¡¼­ ¿¬±¸µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÓ»ó½ÃÇèÀº ´Ù¾çÇÑ °íÇü¾Ï¿¡¼­ ¿©·¯ Á¾¾ç °ü·Ã Ç׿ø, MT1-MMP, EphA2, Nectin-4¿¡ ´ëÇÑ °ÍÀÔ´Ï´Ù.

º» º¸°í¼­´Â ÀÓ»ó½ÃÇèÀÇ »ó, Áö¿ª, ½ºÆù¼­ ´Üü, ¿¬±¸ÁßÀÇ ÀûÀÀÁõ µî, ÀÌ·¯ÇÑ ÀÓ»ó½ÃÇè¿¡ °üÇÑ ÁÖ¸ñÇÒ¸¸ÇÑ Á¤º¸¸¦ ±â·ÏÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇöÀç±îÁöÀÇ ÁÖ¿ä ½ÃÇè °á°úµµ Á¤¸®Çß½À´Ï´Ù. ÀÌ µ¥ÀÌÅÍ´Â ¹ÙÀ̽ÃŬ·çÅå½Å Á¢ÇÕüÀÇ ÀÓ»ó °æ°ú¿Í ±ÔÁ¦Àû À¯¸Á¼ºÀ» ¸íÈ®Çϰí Á¤È®ÇÏ°Ô º¸¿©ÁÝ´Ï´Ù.

±â¼ú Ç÷§Æû, °øµ¿ ¿¬±¸, °è¾à

Bicycle TherapeuticsÀÇ µ¶ÀÚÀûÀÎ Bicycle(R) Ç÷§ÆûÀº Bicycle Toxin Conjugate °³¹ßÀÇ ±â¼úÀû ±â¹ÝÀ» ±¸¼ºÇϰí ÀÖ½À´Ï´Ù. È­ÇÐÀûÀ¸·Î ÇÕ¼ºµÈ ÆéƼµå ±â¼úÀº MMAE ¹× DM1°ú °°Àº ¼¼Æ÷ µ¶¼Ò¿Í °áÇÕµÈ ÀÛ°í ¼±ÅüºÀÌ ³ôÀº °áÇÕÁ¦¸¦ »ý»êÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú, »ý¹°ÇÐÀû Á¦Çü°ú ÀúºÐÀÚÀÇ Áß°£ Ä¡·áÁ¦ Ŭ·¡½º°¡ ž Á¾¾ç ±íÀº °÷À¸·ÎÀÇ Ä§Åõ°¡ °­È­µÇ°í Ŭ¸®¾î·±½º°¡ ÃËÁøµË´Ï´Ù.

Çù·ÂÀº ¿ì¸®ÀÇ Á¢±ÙÀÇ ÇÙ½ÉÀÔ´Ï´Ù. ¿µ±¹ ¾Ï ¿¬±¸ Çùȸ(Cancer Research UK)¿ÍÀÇ »õ·Î¿î °øµ¿ ¿¬±¸¿¡ ÀÇÇØ BT1718Àº Á¦1/2»ó ÀÓ»ó½ÃÇèÀ¸·Î ÀÌÇàÇϰí, ¿µ±¹ ¾Ï ¿¬±¸ Çùȸ(Cancer Research UK)°¡ ÀÓ»ó½ÃÇèÀÇ ½ºÆù¼­°¡ µÇ¾î ÀÚ±ÝÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ FDAÀÇ CMC °³¹ßÁغñ½ÃÇè(CDRP)¿¡µµ Âü¿©Çϰí ÀÖ½À´Ï´Ù.

¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕüÀÇ ¿¬±¸ °³¹ß¿¡ Àû±ØÀûÀÎ ÁÖ¿ä ±â¾÷

ÇöÀç Bicycle Therapeutics´Â Bicycle Toxin ConjugateÀÇ ÀÓ»ó ´Ü°è¿¡ Àû±ØÀûÀ¸·Î Âü¿©ÇÏ´Â À¯ÀÏÇÑ ±â¾÷ÀÔ´Ï´Ù. ¿µ±¹ Ä·ºê¸®Áö¿¡ ¼³¸³µÈ Bicycle Therapeutics´Â ´Ù¾çÇÑ Á¾¾ç¿¡ ÇØ´çÇÏ´Â ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü Æ÷Æ®Æú¸®¿À¸¦ °¡Áø ÀÌ ºÐ¾ßÀÇ ¼¼°è ¸®´õÀÔ´Ï´Ù. ÀÌ È¸»ç°¡ 1¼¼´ë, 2¼¼´ë, 3¼¼´ë ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕüÀÇ °³¹ßÀ» °è¼ÓÇϰí ÀÖ´Â °ÍÀº ÀÌ »õ·Î¿î Ŭ·¡½ºÀÇ Ä¡·á¹ýÀÇ Áøº¸¿¡ ÁÖ·ÂÇϰí ÀÖ´Â °ÍÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. Bicycle Therapeutics´Â ¼¼°è ÀÓ»ó½ÃÇè°ú ¾ç ´ë¼­¾ç ±ÔÁ¦ ´ç±¹ °£ÀÇ »óÈ£ÀÛ¿ëÀ» ÅëÇØ ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕüÀÇ ÇâÈÄ ¹æÇâ°ú ÀáÀç·ÂÀ» ¼¼°èÀûÀ¸·Î ¹àÇô³»°í ÀÖ½À´Ï´Ù.

¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü ºÎ¹®ÀÇ ÇâÈÄ ¹æÇâÀ» Á¦¾ÈÇÏ´Â º¸°í¼­

º» º¸°í¼­¿¡¼­´Â ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü°¡ Precision On Cologe¿¡¼­ ÇʼöÀûÀÎ ½ÅÁø±â¿¹ÀÇ ¹üÁÖÀ̸ç, ÀûÀÀÁõ¿¡ µû¶ó ADC¿¡ ÇÊÀûÇϰųª ADC¸¦ ´É°¡ÇÒ ¼ö ÀÖÀ½À» ¹àÇû½À´Ï´Ù. ºü¸¥ Æ®·° ¹× CDRP ÁöÁ¤°ú °°Àº ±ÔÁ¦ °ü½ÉÀº ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü¿¡ ´ëÇÑ ÀÇ·á ±â°üÀÇ °ü½É Áõ°¡¸¦ ¹Ý¿µÇÕ´Ï´Ù. º´¿ë ¿ä¹ý¿¡ À־ÀÇ ÀÓ»óÀû È¿´ÉÀº ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü°¡ ´Ü±â°£ ³»¿¡ Á¦1¼±ÀÇ ¾Ï Ä¡·á ¿ä¹ýÀÇ ÇʼöÀûÀÎ ºÎºÐÀÌ µÉ °¡´É¼ºÀ» ½Ã»çÇϰí ÀÖ½À´Ï´Ù.

°³¹ßÀÌ ÁøÇàµÇ¸é ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü Ç÷§ÆûÀº Á¾¾çÇÐ À̿ܿ¡µµ ÀÌ¿ë °¡´ÉÇÏ°Ô µÇ¾î °¨¿°ÁõÀ̳ª Ç¥Àû ÆäÀ̷εåÀÇ Àü´ÞÀ» ÇÊ¿ä·Î ÇÏ´Â ±âŸ ÀûÀÀÁõÀ¸·Îµµ À¯¸Á½ÃµË´Ï´Ù. ¿©±â¿¡ Á¦½ÃµÈ ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü ºÐ¾ßÀÇ °³¹ßÀº ±ÔÁ¦ ´ç±¹¿¡ ¹Þ¾Æµé¿©Áö°í ¿ëµµ°¡ È®´ëµÇ°í »ê¾÷°è¿¡ ħÅõÇØ ³ª°¡´Â ±æÀ» ¸íÈ®ÇÏ°Ô º¸¿©ÁÝ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü ¼­¹®

Á¦2Àå ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü-ÀÛ¿ë±âÀüº°

Á¦3Àå ¼¼°èÀÇ ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü Á¶»ç ¹× ½ÃÀå µ¿Çâ : ÀûÀÀÁõº°

Á¦4Àå ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü-µ¶ÀÚÀûÀÎ Ç÷§Æû

Á¦5Àå ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕüÀÇ ÀÓ»ó½ÃÇè °³¿ä

Á¦6Àå ¼¼°èÀÇ ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕüÀÇ ÀÓ»ó ÆÄÀÌÇÁ¶óÀÎ - ±â¾÷, ÀûÀÀÁõ, »óº°

Á¦7Àå ¼¼°èÀÇ ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕüÀÇ ÇöÀç ¹× ¹Ì·¡ ½ÃÀå µ¿Çâ°ú Àü¸Á

Á¦8Àå ¼¼°èÀÇ ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕüÀÇ ¿¬±¸ ¹× Áö¿ªº° ½ÃÀå µ¿Çâ

Á¦9Àå ¼¼°èÀÇ ¹ÙÀ̽ÃŬ µ¶¼Ò Á¢ÇÕü ½ÃÀå ¿ªÇÐ

Á¦10Àå °æÀï ±¸µµ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Bicycle Toxin Conjugates Clinical Trials, Proprietary Platforms & Market Opportunity Insight 2025 Report Highlights:

Need for Bicycle Toxin Conjugates & Why This Report?

The increasing need for safer, more effective, and highly targeted anticancer therapies has driven pharmaceutical discovery towards new therapeutic modalities. Bicycle Toxin Conjugates (BTCs) are a new generation of targeted therapies possessing a distinctive blend of precision, favorable pharmacokinetics, and tumor penetration. Combining the binding affinity of bicyclic peptides and the cytotoxic payloads of chemotherapy drugs, BTCs are engineered to provide highly effective anti-cancer activity with reduced systemic toxicity.

This report is timely and critical as the bicycle toxin conjugates space transitions from initial clinical promise to solid achievements. While the area remains in its infancy, the velocity of clinical advancement, regulatory acceptance, and research investment is increasing. This analysis provides an all-encompassing perspective on where bicycle toxin conjugates are scientifically, clinically, and commercially now and gives stakeholders critical insight into a fast-developing area that can reshape future benchmarks in oncology and beyond.

Clinical Trials Insight Included In Report

The report offers an in-depth summary of the ongoing bicycle toxin conjugates clinical trial landscape, outlining the development of major therapeutic candidates through early- and mid-stage studies. Three bicycle toxin conjugates created by Bicycle Therapeutics, namely BT1718, BT5528, and zelenectide pevedotin (Zele, BT8009), are being studied in early and late-stage clinical trials. These trials are directed against several tumor-associated antigens, MT1-MMP, EphA2, and Nectin-4, in a variety of solid tumors.

This report records notable information on these trials, such as trial phases, geographical regions, sponsoring organizations, and indications being researched. It also summarizes key trial results to date; this data offer a clear, precise view of bicycle toxin conjugates clinical progress and regulatory promise

Technology Platforms, Collaborations and Agreements

Bicycle Therapeutics' proprietary Bicycle(R) platform constitutes the technological underpinning of bicycle toxin conjugates development. The chemically synthesized peptide technology allows small, highly selective binding agents to be generated coupled with cytotoxins such as MMAE and DM1. This results in a class of therapies that are intermediate between biologics and small molecules, showing enhanced deep tumor penetration and accelerated clearance.

Cooperative action is at the core of the firm's approach. A new collaboration with Cancer Research UK has brought BT1718 to Phase 1/2 trials, with CRUK sponsoring and funding the trial. Furthermore, the firm's engagement in the FDA's CMC Development and Readiness Pilot (CDRP).

Major Companies Active In R&D of Bicycle-Toxin Conjugates

Currently, Bicycle Therapeutics is the only company actively working on bicycle toxin conjugates at a clinical stage. Established in Cambridge, UK, the company is the global leader in this area with a portfolio of bicycle toxin conjugates addressing a variety of tumors. Its continued development of first-, second-, and third-generation bicycle toxin conjugates reflects its focus on advancing this new class of therapy. Through global trials and regulatory interaction on both Atlantic sides, Bicycle Therapeutics is outlining the future direction and potential of bicycle toxin conjugates worldwide.

Report Suggesting Future Direction Of Bicycle-Toxin Conjugates Segment

This report identifies bicycle toxin conjugates as an essential up-and-coming category in precision oncology with the potential to either match or even outperform ADCs in some indications. Regulatory interest, including Fast Track and CDRP designation, reflects increasing institutional interest in bicycle toxin conjugates. Clinical efficacy in combination therapies implies bicycle toxin conjugates may become an integral part of front-line cancer regimens within a short while.

As it continues to develop, the bicycle toxin conjugates platform can also be utilized outside of oncology, with promise in infectious disease and other indications that call for targeted payload delivery. The development of the bicycle toxin conjugates segment, as illustrated here, clearly shows a path toward regulatory acceptance, expanded application, and increased industry uptake.

Table of Contents

1. Introduction To Bicycle Toxin Conjugates

2. Bicycle Toxin Conjugates - Mechanism Of Action

3. Global Bicycle Toxin Conjugates Research & Market Trends By Indication

4. Bicycle Toxin Conjugates - Proprietary Platforms

5. Global Bicyclic Toxin Conjugates Clinical Trials Overview

6. Global Bicyclic Toxin Conjugates Clinical Pipeline By Company, Indication & Phase

7. Global Bicycle Toxin Conjugates Current & Future Market Trends Outlook

8. Global Bicycle Toxin Conjugates Research & Market Trends By Region

9. Global Bicycle Toxin Conjugates Market Dynamics

10. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â